ACCESS REALMONEY
Health Care
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Related Articles
- Gopher State's Suit Galls UnitedHealth
- Biolase: Letter Perfect?
- National Health Terms Buyout Bid Inadequate
- Del.icio.us
- Digg
- StumbleUpon
AbiomedABMD late Thursday issued downside revenue guidance for its second quarter ended Sept. 30. The maker of heart-pumping devices forecast sales of $11 million, below Street consensus of $13.3 million in revenue, but a tad higher than reported revenue in the same period last year of $10.9 million. "Our strategic platforms of Impella and AB5000 (consoles and disposables) performed well during the quarter," said CEO Michael Minogue, who added that revenue for BVS (blood pumps) declined. After hours, shares of the Danvers, Mass.-based company slipped 6.7%, or 95 cents, to $14.05. The company will give full second-quarter 2007 results on Nov. 8. Abiomed closed the regular session up 2 cents to $15.
Prosecutors in Minnesota expand an option-backdating case.
An FDA warning suggests case may not be closed.
The company's CEO has offered $30 a share.
Yahoo! is among the most searched stocks on TheStreet.com. Here's what Cramer had to say about the stock recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Ensco International and Echelon have the potential to move higher in coming days.
See who made what calls.
The addition of video is helping telecom companies compete against cable and satellite companies.
The June West Texas Intermediate contract reflects selling pressure ahead of Tuesday's expiration. But stocks in the sector are generally trading higher.
See who made what calls.
Keep on top of the market and the critical information you need to make more profitable investing decisions.
Sponsored by:
RSS
